<DOC>
	<DOCNO>NCT01768858</DOCNO>
	<brief_summary>The main purpose study ass patient ` adherence attitude ( belief ) maintenance therapy schedule Adalimumab monotherapy combination therapy methotrexate investigate whether correlation beliefs adherence maintenance treatment .</brief_summary>
	<brief_title>Assessment Rheumatoid Arthritis , Psoriatic Arthritis , Ankylosing Spondylitis , Plaque Psoriasis , Crohn 's Disease Ulcerative Colitis Patients´ Adherence Attitudes Maintenance Therapy With Scheduled Adalimumab Treatment Routine Clinical Practice</brief_title>
	<detailed_description>This non-interventional , observational study Humira ( adalimumab ) prescribe usual manner accordance term local marketing authorization regard dose , population indication . The assignment patient Humira-containing regimen decide advance current practice . The prescription Humira clearly separate decision include participant study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients age &gt; =18 year RA , PsA , AS , PsO , CD , UC Patients must fulfill international national guideline use BDMARD RA , PsA , AS , PsO , CD , UC ( Chest Xray IGRA interferon gamma release assay PPDskin test negative tuberculosis ) . In addition one follow criterion must fulfil : 1. unsatisfactory DMARD response define failure treatment least two DMARDs include Methotrexate patient RA PsA 2. unsatisfactory NSAID response patient AS 3. unsatisfactory response prior BDMARDs patient RA PsA AS . 4. unsatisfactory response contraindication , intolerance systemic therapy include cyclosporine , methotrexate PUVA patient PsO . Unsatisfactory response despite full adequate course therapy corticosteroid and/or immunosuppressant ; intolerance medical contraindication therapy CD . 5. unsatisfactory response conventional therapy include corticosteroid 6mercaptopurine ( 6MP ) azathioprine ( AZA ) , intolerance medical contraindication therapy UC . Patients cover late version Humira syringe® SPC Humira Pen® SPC ; Patients participate another study program clinical trial . Patients treat Adalimumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Morbus Crohn</keyword>
	<keyword>Adherence</keyword>
	<keyword>Spondylitis</keyword>
	<keyword>Ulcerative colitis</keyword>
	<keyword>Monoclonals</keyword>
	<keyword>Rheumatoid</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Ankylosing</keyword>
	<keyword>Plaque psoriasis</keyword>
	<keyword>Psoriatic</keyword>
	<keyword>Crohn´s disease</keyword>
	<keyword>Antirheumatic Agents</keyword>
</DOC>